When was Rezo founded?

Rezo was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Rezo located?

Rezo is headquartered in San Francisco, United States.

How many employees does Rezo have?

As of May 31, 2026, the latest employee count at Rezo is 44.

Is Rezo a funded company?

Rezo is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jul 21, 2022.

When was the latest funding round of Rezo?

Rezo's latest funding was a $***** Series A round on Jul 21, 2022, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.12B in funding in 2026 to date.

Where does Rezo rank among its competitors?

Rezo ranks 113th amongst 531 active competitors, of which 191 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Rezo?

Rezo's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Rezo - 2026 Company Profile, Team, Funding & Competitors

Rezo is a series A company based in San Francisco (United States), founded in 2021 by Sourav Bandyopadhyay, George Scangos, Nevan Krogan, Jacqueline Fabius, Kevan Shokat, Norbert Bischofberger and Natalia Jura. It operates as an AI-powered genomics platform for targeted disease therapeutics. Rezo has raised $78M in funding from investors like Andreessen Horowitz, SR One and Norwest. The company has 531 active competitors, including 191 funded and 127 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

AI-powered genomics platform for targeted disease therapeutics. The company has a Sequence to Systems to Drugs (SSD) platform that integrates proteomics, genetics, structural biology, chemistry, and bioinformatics to create maps of molecular disease networks, initially focused on solid tumor oncology guided by mutation and allele-specific biomarkers.

Website: rezotx.com
Email ID: *****@rezotx.com

Key Metrics

Founded Year

2021

Location

San Francisco, United States

Stage

Series A

Total Funding

$78M in 1 round

Latest Funding Round

Series A, Jul 21, 2022, $*****

Investors

Andreessen Horowitz & 5 more

Ranked

113^th among 531 active competitors

Employee Count

44 as on May 31, 2026

Similar Companies

Alnylam & 668 more

View Rezo's full profile

Rezo is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rezo Therapeutics, Inc. CIN: 6424956 , United States, Active	Dec 31, 2020	-	-	-
REZO CIN: 40003500473 , Latvia, Deadpooled	Jul 04, 2000	€0 - €1M (As on Dec 31, 2017)	1 (As on Dec 31, 2022)	-

Rezo has raised a total funding of $78M over 1 round. Its latest funding round was a Series A round on Jul 21, 2022 for $*****. 6 investors participated in its latest round. Rezo has 6 institutional investors.

Here is the list of recent funding rounds of Rezo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2022	2238520	Series A	1974450	6988180	9690659	5956339

Access funding benchmarks and valuations. Sign up today!

View details of Rezo's funding rounds and investors

The founders of Rezo are Sourav Bandyopadhyay, George Scangos, Nevan Krogan, Jacqueline Fabius, Kevan Shokat, Norbert Bischofberger and Natalia Jura.

Here are the details of Rezo's key team members:

Sourav Bandyopadhyay: Co-Founder of Rezo. They serve on the board of 1 company.
George Scangos: Co-Founder of Rezo. They serve on the board of 1 company.
Contact Info: 1 email address
Nevan Krogan: Founder and President of Rezo. They serve on the board of 1 company.
Jacqueline Fabius: Co-Founder of Rezo.
Kevan Shokat: Co-Founder of Rezo.

Rezo's Board of Directors

Rezo's board has 7 active members. Norbert Bischofberger, Simeon George, Sourav Bandyopadhyay, George Scangos, Nevan Krogan, Vineeta Agarwala and Nadir Mahmood are independent board members.

Here is the list of Rezo's board of directors:

Name	Type	Representing	Status	Duration
Norbert Bischofberger	Independent board member	-	Current	3y 6m
pesfqdi	Independent board member	-	Current	2y 1m
gbjnqkg	Independent board member	-	Current	1y 1m
evkecqu	Independent board member	-	Current	3y 1m
vkxevon	Independent board member	-	Current	1y 4m
ypwyxkk	Independent board member	-	Current	2y 9m
zuwjqrr	Independent board member	-	Current	2y 7m

View details of Rezo's Founder profiles and Board Members

Rezo's employee count trend

Rezo has 44 employees as of May 26. Here is Rezo's employee count trend over the years:

Uncover Rezo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rezo include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of Rezo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
113th	Rezo 2021, San Francisco (United States), Series A	AI-powered genomics platform for targeted disease therapeutics	$78M	Norwest, Andreessen Horowitz & 4 others	52/100